• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ON-X LIFE TECHNOLOGIES, INC. ON-X PROSTHETIC AORTIC VALVE WITH CONFORM-X SEWING RING AND EXTENDED HOLDER; HEART-VALVE, MECHANICAL

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ON-X LIFE TECHNOLOGIES, INC. ON-X PROSTHETIC AORTIC VALVE WITH CONFORM-X SEWING RING AND EXTENDED HOLDER; HEART-VALVE, MECHANICAL Back to Search Results
Model Number ONXACE-25
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Endocarditis (1834)
Event Date 01/27/2020
Event Type  Injury  
Manufacturer Narrative
This investigation is currently ongoing.Any additional information will be provided in the follow-up report.
 
Event Description
According to the initial report, onxace-25, sn (b)(4) was implanted on (b)(6) 2019 and was explanted and replaced with onxace-27/29, sn (b)(4) on (b)(6) 2020 due to endocarditis.
 
Manufacturer Narrative
The manufacturing records for onxace-25, sn (b)(6) were reviewed and it was confirmed that all records were controlled, available for review, and met all specifications per the device master record.All lots passed functional testing and met release specifications.During the investigation no non-conformances or deviations were noted.According to the implant registration card (irc), an onxace-25, sn (b)(6) was implanted (b)(6) 2019 in the aortic position of a 59-year-old male.On (b)(6) 2020 (1 year 3 days post implant) another irc indicated onxace-27/29, sn (b)(6) was reported as implanted in the aortic position of the same patient.It was presumed that the initial on-x valve was explanted.Subsequent information requested of the institution confirmed that the onxace-25 had been explanted, that the reason was endocarditis, that the valve had not been deficient, and that the patient was discharged.Of note, it is unlikely the on-x valve was the source of the infection as on-x valves undergo a validated terminal sterilization process during manufacturing.The general reason to explant a prosthesis due to endocarditis (infection) is paravalvular leak (pvl) as a result of deterioration of the annular tissue that anchors the valve in place, though that is not explicitly stated in this case.The instructions for use [ifu] for the on-x valve acknowledge endocarditis as a risk factor (as well as prosthetic perivalvular leak) in prosthetic valve replacement which may result in reoperation and explantation.The historical record shows an occurrence rate of 1.2%/patient-year for endocarditis and 0.6%/patient-year for major pvl for recipients of rigid heart valve substitutes [iso 5840:2005].We have no evidence of any valvular malfunction.Endocarditis is the underlying cause of the explantation and replacement of the original on-x prosthesis.A risk assessment was performed.It is unlikely the on-x valve was the source of the infection as on-x valves undergo a validated terminal sterilization procedure during manufacturing.The review of the device history record (dhr) found that the valve met all specifications and testing requirements.There were no issues found in the manufacture of the device.The on-x ifu lists endocarditis as a potential adverse event.The reported event is also identified in the on-x heart valve design fmea.The on-x valve risk management file thoroughly identifies the process and product hazards for approved indications.Each individual hazard is mitigated and reduced as far as possible by design and process.Post production residual risk is communicated in the product¿s labeling and ifu.This event does not identify additional hazards or modify the probability or severity of existing hazards.This report is being submitted as required by federal regulations and does not constitute an admission that the device caused or contributed to the reported event.Furthermore, this report reflects the event as alleged by the complainant and does not imply that the information reported to cryolife is accurate or has been confirmed by cryolife.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ON-X PROSTHETIC AORTIC VALVE WITH CONFORM-X SEWING RING AND EXTENDED HOLDER
Type of Device
HEART-VALVE, MECHANICAL
Manufacturer (Section D)
ON-X LIFE TECHNOLOGIES, INC.
1300 e. anderson ln., bldg. b
austin TX 78752
MDR Report Key9817667
MDR Text Key183564559
Report Number1649833-2020-00001
Device Sequence Number1
Product Code LWQ
Combination Product (y/n)N
PMA/PMN Number
P000037
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative
Type of Report Initial,Followup
Report Date 04/14/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model NumberONXACE-25
Was Device Available for Evaluation? No
Initial Date Manufacturer Received 02/19/2020
Initial Date FDA Received03/11/2020
Supplement Dates Manufacturer Received02/19/2020
Supplement Dates FDA Received04/14/2020
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Outcome(s) Other; Required Intervention;
Patient Age60 YR
-
-